Skip to content

Adjuvance Technologies

Empowering health.

About Us
Our Technology
Our Leadership
- Management Team
- Board of Directors
Investors & Media
Contact

Nature Chemistry: Development of a minimal saponin vaccine adjuvant based on QS-21

By jgardnerJune 1, 2014Publications

Nature Chemistry: Development of a minimal saponin vaccine adjuvant based on QS-21

Adjuvance cofounders report the design, develop and adjuvant activity of novel, truncated QS-21 analogs.

Post navigation

Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer

Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol

Recent Posts

ADJUVANCE TECHNOLOGIES ANNOUNCES $20 MILLION SERIES A INVESTMENT FROM MORNINGSIDE VENTURE INVESTMENTS
Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine
NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine
Vaccine Adjuvant Systems containing monophosphoryl lipid A andQS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination
Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol

Copyright © All rights reserved. Theme Businessbiz by Sensational Theme